Direkt zum Inhalt
Merck
  • Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

The Journal of pharmacology and experimental therapeutics (2016-12-15)
J Di Salvo, H Nagabukuro, L A Wickham, C Abbadie, J A DeMartino, A Fitzmaurice, L Gichuru, A Kulick, M J Donnelly, N Jochnowitz, A L Hurley, A Pereira, A Sanfiz, G Veronin, K Villa, J Woods, B Zamlynny, E Zycband, G M Salituro, T Frenkl, A E Weber, S D Edmondson, M Struthers
ZUSAMMENFASSUNG

Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
CL 316243 Hydrat, ≥98% (HPLC), powder
Sigma-Aldrich
Triglycerid- und freie Glycerin-Kits und -Reagenzien, 1 kit sufficient for 1000 reactions
Sigma-Aldrich
Methoctramine hydrate, ≥97% (NMR), solid
Sigma-Aldrich
Darifenacin hydrobromide, ≥98% (HPLC)